Literature DB >> 29957021

Getting to the heart of myofibroblast differentiation: implications for scleraxis in ECM remodeling and therapeutic targeting.

Ashley L Eadie1, Allison J Titus1, Keith R Brunt1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29957021      PMCID： PMC6297817          DOI： 10.1152/ajpheart.00381.2018

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN： 0363-6135            Impact factor:   4.733


× No keyword cloud information.
  11 in total

1.  The basic helix-loop-helix transcription factor scleraxis regulates fibroblast collagen synthesis.

Authors:  Leon Espira; Lise Lamoureux; Stephen C Jones; Robert D Gerard; Ian M C Dixon; Michael P Czubryt
Journal:  J Mol Cell Cardiol       Date:  2009-04-10       Impact factor: 5.000

2.  Scleraxis regulates Twist1 and Snai1 expression in the epithelial-to-mesenchymal transition.

Authors:  Danah S Al-Hattab; Hamza A Safi; Raghu S Nagalingam; Rushita A Bagchi; Matthew T Stecy; Michael P Czubryt
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-15       Impact factor: 4.733

Review 3.  A primer on current progress in cardiac fibrosis.

Authors:  Danah Al Hattab; Michael P Czubryt
Journal:  Can J Physiol Pharmacol       Date:  2017-03-08       Impact factor: 2.273

4.  Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction.

Authors:  Sih Min Tan; Yuan Zhang; Kim A Connelly; Richard E Gilbert; Darren J Kelly
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-02-12       Impact factor: 4.733

5.  Central-acting therapeutics alleviate respiratory weakness caused by heart failure-induced ventilatory overdrive.

Authors:  Andrew J Foster; Mathew J Platt; Jason S Huber; Ashley L Eadie; Alicia M Arkell; Nadya Romanova; David C Wright; Todd E Gillis; Coral L Murrant; Keith R Brunt; Jeremy A Simpson
Journal:  Sci Transl Med       Date:  2017-05-17       Impact factor: 17.956

6.  The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors.

Authors:  Asha Acharya; Seung Tae Baek; Guo Huang; Banu Eskiocak; Sean Goetsch; Caroline Y Sung; Serena Banfi; Marion F Sauer; Gregory S Olsen; Jeremy S Duffield; Eric N Olson; Michelle D Tallquist
Journal:  Development       Date:  2012-05-09       Impact factor: 6.868

7.  Electrotonic coupling of excitable and nonexcitable cells in the heart revealed by optogenetics.

Authors:  T Alexander Quinn; Patrizia Camelliti; Eva A Rog-Zielinska; Urszula Siedlecka; Tommaso Poggioli; Eileen T O'Toole; Thomas Knöpfel; Peter Kohl
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-07       Impact factor: 11.205

8.  Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart.

Authors:  Xing Fu; Hadi Khalil; Onur Kanisicak; Justin G Boyer; Ronald J Vagnozzi; Bryan D Maliken; Michelle A Sargent; Vikram Prasad; Iñigo Valiente-Alandi; Burns C Blaxall; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2018-04-16       Impact factor: 14.808

9.  Genetic lineage tracing defines myofibroblast origin and function in the injured heart.

Authors:  Onur Kanisicak; Hadi Khalil; Malina J Ivey; Jason Karch; Bryan D Maliken; Robert N Correll; Matthew J Brody; Suh-Chin J Lin; Bruce J Aronow; Michelle D Tallquist; Jeffery D Molkentin
Journal:  Nat Commun       Date:  2016-07-22       Impact factor: 14.919

10.  Pathophysiological Mapping of Experimental Heart Failure: Left and Right Ventricular Remodeling in Transverse Aortic Constriction Is Temporally, Kinetically and Structurally Distinct.

Authors:  Mathew J Platt; Jason S Huber; Nadya Romanova; Keith R Brunt; Jeremy A Simpson
Journal:  Front Physiol       Date:  2018-05-15       Impact factor: 4.566
View more
  1 in total

1.  Depletion of Scleraxis-lineage cells during tendon healing transiently impairs multi-scale restoration of tendon structure during early healing.

Authors:  Antonion Korcari; Samantha Muscat; Elizabeth McGinn; Mark R Buckley; Alayna E Loiselle
Journal:  PLoS One       Date:  2022-10-14       Impact factor: 3.752
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.